What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-07-27 compared with 2023-04-27 · 46 added, 11 removed, 30 unchanged (66% of the section changed)

ITEM 5 - OTHER INFORMATION

Trading Plans

During the three months ended June 30, 2023, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as described in the table below:

Character of Trading Arrangement

Name Title Adoption Date Rule 10b5-1* Non-Rule 10b5-1** Total Shares to be Sold Expiration Date (1)

Executive Vice President, Global Business Services, IT Quality and Regulatory Affairs

5/5/2023 X 3,258 5/6/2024

5/30/2023 X 9,568 5/30/2025

6/13/2023 X 600 6/13/2024

* Intended to satisfy the affirmative defense of Rule 10b5-1(c)

** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

(1) Except as indicated by footnote, each trading arrangement permitted or permits transactions through and including the earlier to occur of (a) the completion of all purchases or sales or (b) the date listed in the table.

Each new Rule 10b5-1 Plan that was adopted in the above table includes a representation from Ms.

Heller, and Messrs.

Abbey and Altman respectively, to the broker administering the plan that he or she was not in

possession of any material nonpublic information regarding Dexcom or the securities subject to the Rule 10b5-1 Plan at the time the Rule 10b5-1 Plan was entered into.

A similar representation was made to Dexcom in connection with the adoption of the Rule 10b5-1 Plan under Dexcom’s insider trading policy.

Those representations were made as of the Adoption Date set forth above, and speak only as of that date.

In making those representations, there is no assurance with respect to any material nonpublic information of which the directors and officers was unaware, or with respect to any material nonpublic information acquired by the above directors and officers or Dexcom after the date of the representation.

Once executed, transactions under a Rule 10b5-1 Plan adopted during the period described above will be disclosed publicly through Form 4 and/or Form 144 filings with the SEC in accordance with applicable securities laws, rules, and regulations.

Except as may be required by law, Dexcom does not undertake any obligation to update or report any modification, termination, or other activity under current or future Rule 10b5-1 plans that may be adopted by Ms.

Heller, Messrs.

Abbey and Altman, respectively, or other officers or directors of Dexcom.

ITEM 6 - EXHIBITS

3 unchanged sentences

Number Provided

Amendment Number Nine to Non-Exclusive Wholesale Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc.

and RGH Enterprises, LLC.

Amendment Number Ten to Non-Exclusive Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc.

Restated Certificate of Incorporation of DexCom, Inc.

8-K 000-51222 June 10, 2022 3.1 —

Indenture dated May 5, 2023 between DexCom, Inc.

Bank Trust Company, National Association (including the form of 0.375% Convertible Senior Notes due 2028).

8-K 000-51222 May 5, 2023 4.1 —

Amended and Restated Severance and Change in Control Plan effective June 1, 2017, and as amended on May 18, 2023.

8-K 000-51222 May 19, 2023 10.1 —

Amendment Number Eleven to Non-Exclusive Distribution Agreement, dated March 15 , 2023, by and between DexCom, Inc.

and RGH E nterprises , LLC .

Amendment Number Fourteen to Amended and Restated Non-Exclusive Distribution Agreement, dated April 1, 2023, by and between DexCom, Inc.

and Byram Healthcare.

Amendment Number Twelve to Non-Exclusive Distribution Agreement, dated May 15 , 2023, by and between DexCom, Inc.

and RGH Enterprises, LLC .

Amendment Number Twelve to Amended and Restated Non-Exclusive Distribution Agreement, dated February 1, 2023, by and between DexCom, Inc.

Amendment Number Thirteen to Amended and Restated Non-Exclusive Distribution Agreement, dated June 1, 2023, by and between DexCom, Inc.

and Byram Healthcare.

First Amendment to Second Amended and Restated Credit Agreement, dated June 1, 2023 by and between DexCom, Inc.

and JPMorgan Chase Bank National Association .

Amendment Number Fif teen to Amended and Restated Non-Exclusive Distribution Agreement, dated June 1 5 , 2023, by and between DexCom, Inc.

and Byram Healthcare.

Incorporated by Reference

Number Exhibit Description Form File No.

Filing Exhibit

Number Provided

Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule 13a-14(a).

8 unchanged sentences

101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X

Incorporated by Reference

Number Exhibit Description Form File No.

Filing Exhibit

Number Provided

101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X

101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X

104 Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 is formatted in Inline XBRL

104 Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 is formatted in Inline XBRL

* Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

2 unchanged sentences

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

April 27, 2023 By:

July 27, 2023 By:

Chairman of the Board of Directors,

1 unchanged sentence

(Principal Executive Officer)

April 27, 2023 By:

July 27, 2023 By:

/s/ JEREME M.

2 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information